Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 7/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 18/20 | 0.88 |
| ▸ | PTGIR | P43119 | 3/20 | 0.88 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Domitroban SCHEMBL361564 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL3380908 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL7595949 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL9198684 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL13658118 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL9875564 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL361563 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2232264 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2232269 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL7600963 | 0.99 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109543-A1 | Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination | OGLETREE MARTIN L (US) | 2003-06-12 | — | — | US | claimed |
| US-20030050305-A1 | Thromboxane inhibitors, compositions and methods of use | NITROMED, INC. | 2003-03-13 | — | — | US | claimed |
| US-5462726-A | Suppressing vasoconstriction | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-10-31 | — | — | US | claimed |
| EP-0448274-A2 | Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for the treatment of ulcerative gastrointestinal conditions | E.R. SQUIBB & SONS, INC. (US) | 1991-09-25 | — | — | EP | claimed |
| JP-3017054-A | — | — | None | — | — | JP | disclosed |
| JP-2160758-A | — | — | None | — | — | JP | disclosed |
| US-9834820-B2 | Methods for the treatment and diagnosis of bone mineral density related diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-12-05 | — | — | US | disclosed |
| EP-2227560-B1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-10-18 | — | — | EP | disclosed |
| US-20150104437-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | Universite De Paris (FR) | 2015-04-16 | — | — | US | disclosed |
| US-20100284991-A1 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-11-11 | — | — | US | disclosed |
| EP-2227560-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2010-09-15 | — | — | EP | disclosed |
| EP-2146573-A1 | UNIT DOSE FORMULATIONS AND METHODS OF TREATING AND PREVENTING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS | Portola Pharmaceuticals, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| US-5462726-A | Suppressing vasoconstriction | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0453960-B1 | Sulfonylamino substituted bicyclyl hydroxamic acid derivatives | SHIONOGI & CO (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5312818-A | (Interphenylene)7-oxabicycloheptane substituted (di)amide prostaglandin analog | E. R. SQUIBB & SONS, INC. (US) | 1994-05-17 | — | — | US | disclosed |
| US-5137914-A | Vasodilation, anticoagulants, bronchodilator agents | SHIONOGI & CO., LTD. (JP) | 1992-08-11 | — | — | US | disclosed |
| EP-0453960-A1 | Sulfonylamino substituted bicyclyl hydroxamic acid derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1991-10-30 | — | — | EP | disclosed |
| EP-0448274-A2 | Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for the treatment of ulcerative gastrointestinal conditions | E.R. SQUIBB & SONS, INC. (US) | 1991-09-25 | — | — | EP | disclosed |
| JP-H0317054-A | STABLE CRYSTALLINE SALT AND THROMBOXANE ACCEPTOR ANTAGONIST CONTAINING SAME SALT | SHIONOGI & CO LTD | 1991-01-25 | — | — | JP | disclosed |
| JP-H02160758-A | STABLE CRYSTALLINE SALT AND THROMBOXANE ACCEPTOR ANTAGONIST CONTAINING SAME SALT | SHIONOGI & CO LTD | 1990-06-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100284991-A1 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases | TBXAS1, TBXA2R, HPGDS | TBXA2R 2/4885PTGDR 56/4885PTGIR 25/4885 |
| US-20030109543-A1 | Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination | PTAFR, TBXA2R, PLAT | TBXA2R 2/4885PTGDR 28/4885PTGIR 6/4885 |
| US-20150104437-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | TBXAS1, TBXA2R, HPGDS | TBXA2R 2/4885PTGDR 97/4885PTGIR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.